220 related articles for article (PubMed ID: 35028614)
1. TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.
Beatson RE; Parente-Pereira AC; Halim L; Cozzetto D; Hull C; Whilding LM; Martinez O; Taylor CA; Obajdin J; Luu Hoang KN; Draper B; Iqbal A; Hardiman T; Zabinski T; Man F; de Rosales RTM; Xie J; Aswad F; Achkova D; Joseph CR; Ciprut S; Adami A; Roider HG; Hess-Stumpp H; Győrffy B; Quist J; Grigoriadis A; Sommer A; Tutt ANJ; Davies DM; Maher J
Cell Rep Med; 2021 Dec; 2(12):100473. PubMed ID: 35028614
[TBL] [Abstract][Full Text] [Related]
2. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
[TBL] [Abstract][Full Text] [Related]
3. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.
Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V
J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793
[TBL] [Abstract][Full Text] [Related]
5. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
Kabelitz D; Wesch D; Pitters E; Zöller M
J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
[TBL] [Abstract][Full Text] [Related]
6. Prospects for immunotherapy of acute myeloid leukemia using γδ T cells.
Halim L; Parente-Pereira AC; Maher J
Immunotherapy; 2017 Jan; 9(2):111-114. PubMed ID: 28128710
[No Abstract] [Full Text] [Related]
7. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
8. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
10. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
11. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
12. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
14. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
16. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
17. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
18. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
19. Higher TIGIT+ γδ T
Hou Q; Wang P; Kong X; Chen J; Yao C; Luo X; Li Y; Jin Z; Wu X
Front Immunol; 2024; 15():1321126. PubMed ID: 38711501
[TBL] [Abstract][Full Text] [Related]
20. IL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway.
Wu K; Zhao H; Xiu Y; Li Z; Zhao J; Xie S; Zeng H; Zhang H; Yu L; Xu B
Int Immunopharmacol; 2019 Apr; 69():136-142. PubMed ID: 30708194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
